{"title":"Antigen anisotropy: The overlooked geometric determinant of vaccine immunogenicity and fidelity.","authors":"Daniel Santiago","doi":"10.1080/21645515.2026.2638640","DOIUrl":null,"url":null,"abstract":"<p><p>Antigen anisotropy, the directional dependence of protein conformation, epitope exposure, and conformational dynamics, is an under-appreciated determinant of vaccine immunogenicity. Preserving this geometric fidelity may influence outcomes such as neutralization breadth, affinity maturation, and B/T-cell response quality. Native antigens engage B-cell receptors, T-cell receptors, and MHC through oriented interactions that rely on spatial and dynamic constraints for effective immune recognition. This framework is increasingly relevant amid widespread use of nucleoside-modified mRNA vaccines, as recent studies suggest platform-specific deviations in antigen geometry and processing. Platform interventions including chemical inactivation (e.g., formaldehyde and β-propiolactone), formulation and storage conditions, and mRNA design choices (e.g., N<sup>1</sup>-methylpseudouridine incorporation, codon optimization) can introduce perturbations that influence folding, glycan shielding, epitope presentation, and hydrodynamic behavior. These effects can generate antigen ensembles that diverge from native forms, and may plausibly contribute to differences in response breadth and quality. Prioritizing anisotropy preservation offers a complementary design principle for next generation vaccines, one that seeks to more closely recapitulate the geometric and dynamic features of natural infection and may improve the predictability and durability of protective immunity.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"22 1","pages":"2638640"},"PeriodicalIF":4.2000,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12969738/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21645515.2026.2638640","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Antigen anisotropy, the directional dependence of protein conformation, epitope exposure, and conformational dynamics, is an under-appreciated determinant of vaccine immunogenicity. Preserving this geometric fidelity may influence outcomes such as neutralization breadth, affinity maturation, and B/T-cell response quality. Native antigens engage B-cell receptors, T-cell receptors, and MHC through oriented interactions that rely on spatial and dynamic constraints for effective immune recognition. This framework is increasingly relevant amid widespread use of nucleoside-modified mRNA vaccines, as recent studies suggest platform-specific deviations in antigen geometry and processing. Platform interventions including chemical inactivation (e.g., formaldehyde and β-propiolactone), formulation and storage conditions, and mRNA design choices (e.g., N1-methylpseudouridine incorporation, codon optimization) can introduce perturbations that influence folding, glycan shielding, epitope presentation, and hydrodynamic behavior. These effects can generate antigen ensembles that diverge from native forms, and may plausibly contribute to differences in response breadth and quality. Prioritizing anisotropy preservation offers a complementary design principle for next generation vaccines, one that seeks to more closely recapitulate the geometric and dynamic features of natural infection and may improve the predictability and durability of protective immunity.
期刊介绍:
(formerly Human Vaccines; issn 1554-8619)
Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics.
Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.